Suchergebnisse - "Shi, Yuankai"

PubPharm (531)

81

Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma

enthalten in: Molecular diagnosis & therapy | 2022

von Chen, H. | Qin, Y. | Liu, P. | +8

82

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC : A Phase 2b Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Wu, S. | Wang, K. | +46

83

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC : Results From the FURLONG Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Chen, G. | Wang, X. | +19

84

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer : a phase I dose-escalation and dose-expansion study

enthalten in: BMC cancer | 2022

von Zhang, W. | Han, X. | Yang, L. | +5

85

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

enthalten in: BMC cancer | 2022

von Zhang, W. | Han, X. | Yang, L. | +5

86

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

enthalten in: BMC cancer | 2022

von Zhang, W. | Han, X. | Yang, L. | +5

87

A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma

enthalten in: Asia-Pacific journal of clinical oncology | 2022

von Tao, Y. | Chen, H. | Zhou, Y. | +10

88

Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC : A Multicenter, Single-Arm, Phase 2b Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Li, B. | Wu, L. | +38

89

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer : A real-world study

enthalten in: Thoracic cancer | 2022

von Feng, Y. | Huang, L. | Zhu, H. | +3

90

Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer

enthalten in: Journal of cancer research and therapeutics | 2022

von Xu, J. | Liu, X. | Yang, S. | +1